Details of the Drug | DrugMAP

General Information of Drug (ID: DMTN4TK)

Drug Name

ANX-510

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C20H23N7O6
Canonical SMILES: C1C2CN(CN2C3=C(N1)N=C(NC3=O)N)C4=CC=C(C=C4)C(=O)NC(CCC(=O)O)C(=O)O
InChI: 1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12?,13-/m0/s1
InChIKey: QYNUQALWYRSVHF-ABLWVSNPSA-N

Cross-matching ID

PubChem CID: 135400185
ChEBI ID: CHEBI:20502
CAS Number: 3432-99-3
TTD ID: D01YKI

References

1	ClinicalTrials.gov (NCT00337389) Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.. U.S. National Institutes of Health.